ArticleBMC pulmonary medicine2025
Factors related to the progression of chronic obstructive pulmonary disease: a retrospective case-control study.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review of risk factors and prediction models for multidrug-resistant bacterial pulmonary infections in patients with chronic obstructive pulmonary disease.The Journal of international medical research · 2026Review
- Health inequities in the comorbid association between pneumoconiosis and chronic obstructive pulmonary disease: a nationwide study of age-related heterogeneity.Respiratory research · 2026Article
- COPD stage progression and regression: a multistate transition analysis of the COPDGene cohort.American journal of respiratory and critical care medicine · 2026Article
- Article
- Development and Validation of a Predictive Nomogram for Progression from Pre-COPD to Spirometric COPD: A Multicenter Retrospective Cohort Study.International journal of chronic obstructive pulmonary disease · 2026Article
- Symptom trajectory types during recovery from acute exacerbation of COPD and their association with systemic inflammatory burden and prognosis.Frontiers in cell and developmental biology · 2026Article
- Predictive value of admission levels of IL-6 and PCT combined with the peri-treatment change in NLR (ΔNLR) for hospital length of stay in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesTo explore the factors related to the progression of chronic obstructive pulmonary disease (COPD).
methods80 COPD patients treated between January 2020 and December 2022. The patients' pulmonary functions at their first hospital admission were categorized into four groups: Grade I, Grade II, Grade III and Grade IV. Each group was further divided into a progression group and a non-progression group based on the disease progression over one year or several years of follow-up. Patients with other respiratory diseases, malignant tumors, severe heart, kidney, liver dysfunctions, or immune deficiencies affecting the prognosis were excluded. General information, clinical data, treatment data, and statistical analysis of the patients.
resultsIn comparison with the non-progression group, the progression group had significantly higher age, smoking behavior, COPD history, hemoptysis history, CRP levels, IL-6 levels, and Pneumonia Severity Index (PSI) scores, exhibiting significantly lower FEV1, FEV1% predicted, PaO2, and PaCO2. More frequent use of antibiotics, corticosteroids, oxygen therapy, and mechanical ventilation were observed in the progression group than that in the non-progression group (P < 0.05). As a consequence, the progression group had a worse prognosis as indicated by higher hospitalization costs, longer hospital stay, and higher rate of acute exacerbations than the non-progression group (P < 0.05). Multifactorial logistic regression analysis showed that age ≥ 65 years, PSI score ≥ 130 points, and multidrug-resistant bacteria infection were independent risk factors for the progression of COPD (P < 0.05).
conclusionsOlder COPD patients, higher PSI score, and multidrug-resistant bacteria infection have a worse prognosis and need more intensive treatment and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.